Challenges in beta-Lactamase Mediated Resistance

$311,850R01FY2014AINIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications & trials

Paper 39162493 Paper 39160175 Paper 38990013 Paper 38871227 Paper 38853891 Paper 38742824 Paper 38496545 Paper 38373290 Paper 38370743 Paper 37850746 Paper 37653052 Paper 37503046 Paper 37188957 Paper 37067435 Paper 36399436 Paper 36073814 Paper 36030268 Paper 35899052 Paper 35610334 Paper 35435707 Paper 35358221 Paper 35327400 Paper 35105408 Paper 35099271 Paper 35073757 Paper 34872351 Paper 34825621 Paper 34767753 Paper 34653211 Paper 34579567 Paper 34531538 Paper 34522980 Paper 34355567 Paper 34310884 Paper 34044590 Paper 33789206 Paper 33782013 Paper 33637791 Paper 33593978 Paper 33576025 Paper 33468463 Paper 33431411 Paper 33257320 Paper 33245333 Paper 33021591 Paper 33011051 Paper 33011048 Paper 32964066 Paper 32890839 Paper 32848010 Paper 32848008 Paper 32681170 Paper 32502340 Paper 32500360 Paper 32464664 Paper 32459878 Paper 32420736 Paper 32393499 Paper 32384624 Paper 32349291 Paper 32152078 Paper 32152075 Paper 32151332 Paper 32122888 Paper 32098688 Paper 31852760 Paper 31802119 Paper 31744917 Paper 31740555 Paper 31722380 Paper 31712217 Paper 31530672 Paper 31504587 Paper 31399590 Paper 31396168 Paper 31383666 Paper 31303191 Paper 31266860 Paper 31235626 Paper 31219148 Paper 31182530 Paper 31099835 Paper 31085518 Paper 30994094 Paper 30988147 Paper 30974813 Paper 30914511 Paper 30869058 Paper 30862744 Paper 30858223 Paper 30783798 Paper 30772921 Paper 30659188 Paper 30631796 Paper 30611868 Paper 30552637 Paper 30538183 Paper 30420211 Paper 30348667 Paper 30323050

Abstract

DESCRIPTION (provided by applicant): Despite progress in the discovery and design of b-lactams, b-lactamases continue to pose the most significant threat to our antibiotic armamentarium. Among the serine b-lactamases, the most widespread and problematic are the class A extended-spectrum (ES) ¿-lactamases, the AmpC (class C) cephalosporinases, and the ES AmpCs. These ¿-lactamases are found in ceftazidime resistant Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., Acinetobacter baumannii, and Pseudomonas aeruginosa. In this proposal we will continue our work with boronic acid transition state inhibitors (BATSIs) as molecular probes to target the ES SHV of K. pneumoniae and the AmpC of P. aeruginosa, PDC-3. Our central hypothesis is that a better understanding of the molecular details of catalysis and inhibition of ¿-lactamase enzymes can lead to the design of more effective inhibitors. With this, we formulate the following specific aims: 1. Complete our studies of ES SHV ¿-lactamases by testing novel BATSIs possessing unique R1 side chains. We will use information obtained from susceptibility tests, kinetics, and X-ray crystallography to inform the design of novel functionalities that improve inhibitor affinity and specificity. 2. Define the sequence requirements, molecular, and kinetic interactions that characterize the catalysis and inhibition of PDC-3 ¿-lactamase; a) To understand the interactions of PDC-3 with cephalosporins, carbapenems, and BATSIs on a deeper level, we will test the role of Thr105Ala, Thr289, Asn343, Asn346 and Arg349 in PDC-3 using site- saturation and Ala replacement mutagenesis. b) To investigate the properties of PDC-3 that permit the evolution of the ES and carbapenemase profile, we will introduce specific deletion mutations into the R2-loop of this PDC (D 303 - 306); 3. Determine the apo crystal structure of PDC-3 and the structure of PDC-3 complexed with BATSIs possessing ceftazidime (LP06) and cefotaxime R1 side chains. This work defines important structure-function relationships in class A and C ¿-lactamases and brings us closer to understanding the evolution of the ES cephalosporinases in the clinic as well as discovering effective inhibitors for this challenging drug target. We chose these ¿-lactamases as they are among the most important class A and class C enzymes in Gram-negative bacteria.

View original record on NIH RePORTER →